Alzheon Inc.
Clinical trials sponsored by Alzheon Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new oral drug reach the brain safely? first human test of ALZ-507 Results expected Oct 2026 (estimated)
-
New pill targets Alzheimer's in High-Risk gene carriers
Disease control CompletedThis study tested an oral drug called ALZ-801 in 84 people with early Alzheimer's who carry the APOE4 gene variant, which increases risk. Researchers measured changes in blood and brain scan markers of Alzheimer's over 65 weeks to see if the drug slows disease progression. The go…
Phase 2 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for Alzheimer's? drug targets High-Risk gene carriers
Disease control CompletedThis study tested an experimental drug called ALZ-801 in 325 people with early Alzheimer's disease who carry two copies of the APOE4 gene, a strong risk factor. Participants received either the drug or a placebo for a year. Researchers measured changes in memory, thinking, and da…
Phase 3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC